NECTA Virtual Drug Development Meeting Program- WELCOME
8-810 Introduction - Dr Anthony Joshua
810-830 “Site Australia” – Advantages of doing trials in Australia – Dr Jayesh Desai
PLENARY SESSION
Session 1 Chair Dr Charlotte Lemech – Scientia Clinical Research
830-915 Dr Tobi Arkenau - Strategies to strengthen the anti-tumour immune response
915-1000 Dr Teresa Lavalle - Advancing IO treatment for Cancer Patients: Opportunities and Challenges
100-1045 Dr Chee Lee - Designing Dose Finding Phase 1 Clinical Trials
1045-1115 Discussion
1115-1130 Break
Session 2 Chair Dr James Lynam - Hunter Cancer Alliance
1130-1150 Pipeline 1 - AstraZeneca
1150-1210 Pipeline 2 - MSD - The Role of the HIF2A pathway in the cancer cycle
1210-1240 Break
Session 3 Chair Dr Rasha Cosman - Kinghorn Cancer Centre
1240-110 Dr Aaron Hansen Integrating the patient perspective into Phase 1 Studies
110-140 Dr Herbert Loong Challenges, Opportunities & Ethical Considerations of Early Phase Oncology Trials.
140-155 Break
Session 4 Chair Dr James Lynam, Hunter Cancer Alliance
155-215 Pipeline 3 - CStone
215-235 Pipeline 4 - Bristol Myers Squibb
Session 5 Chair Professor Hui Gan, ONJCRI
235-305 Dr Michael Coory – ORBIS and provisional marketing approvals for cancer medicine
305-335 Shelley Burnett - Moving Early Phase Trials Forward in NSW
335-405 Dr Andrew Wilson – The PBS and drug reimbursement - Perspectives
405-430 End
8-810 Introduction - Dr Anthony Joshua
810-830 “Site Australia” – Advantages of doing trials in Australia – Dr Jayesh Desai
PLENARY SESSION
Session 1 Chair Dr Charlotte Lemech – Scientia Clinical Research
830-915 Dr Tobi Arkenau - Strategies to strengthen the anti-tumour immune response
915-1000 Dr Teresa Lavalle - Advancing IO treatment for Cancer Patients: Opportunities and Challenges
100-1045 Dr Chee Lee - Designing Dose Finding Phase 1 Clinical Trials
1045-1115 Discussion
1115-1130 Break
Session 2 Chair Dr James Lynam - Hunter Cancer Alliance
1130-1150 Pipeline 1 - AstraZeneca
1150-1210 Pipeline 2 - MSD - The Role of the HIF2A pathway in the cancer cycle
1210-1240 Break
Session 3 Chair Dr Rasha Cosman - Kinghorn Cancer Centre
1240-110 Dr Aaron Hansen Integrating the patient perspective into Phase 1 Studies
110-140 Dr Herbert Loong Challenges, Opportunities & Ethical Considerations of Early Phase Oncology Trials.
140-155 Break
Session 4 Chair Dr James Lynam, Hunter Cancer Alliance
155-215 Pipeline 3 - CStone
215-235 Pipeline 4 - Bristol Myers Squibb
Session 5 Chair Professor Hui Gan, ONJCRI
235-305 Dr Michael Coory – ORBIS and provisional marketing approvals for cancer medicine
305-335 Shelley Burnett - Moving Early Phase Trials Forward in NSW
335-405 Dr Andrew Wilson – The PBS and drug reimbursement - Perspectives
405-430 End